ATTACHMENT 1 COMMON CHEMO AGENTS.xlsx
XLSX spreadsheet 11 KB Posted
- Attached to
- Q517--Hazardous Compounding Federal contract opportunity
- Solicitation number
- 36C25624Q1195
About this file
The provided document is an attachment listing common chemotherapy agents, which appears to be related to the federal contract opportunity for "Q517--Hazardous Compounding". The contract opportunity is a solicitation issued by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 for medical hazardous compounding services.
The attachment provides a comprehensive list of over 100 chemotherapy agents, including both generic and brand names. This suggests the contract may involve the supply or compounding of a wide range of chemotherapy drugs. However, the document does not provide any further details about the specific requirements, response dates, pricing terms, or other salient information related to the federal contract opportunity.
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| ATTACHMENT 5 - QUALITY ASSURANCE SURVEILLANCE PLAN.docx | DOCX document | |
| ATTACHMENT 4 PAST PERFORMACE QUESTIONAIRE.docx | DOCX document | |
| ATTACHMENT 3 LIST OF PAST PERFORMANCE REFERENCES.docx | DOCX document | |
| 36C25624Q1195.docx | DOCX document | |
| ATTACHMENT 2 - NATIONAL PBM CSPS ASSESSMENT GUIDE.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| SOLICITATION 36C25619Q1211 |
| COMMON CHEMO AGENTS |
| Ado-trastuzumab |
| Alglucosidase alfa |
| Arsenic Trioxide |
| Atezolizumab |
| Azacitidine |
| Belinostat |
| Bendamustine |
| Bendamustine |
| Bevacizumab |
| Bevacizumab-awwb |
| Bevacizumab-bvzr |
| Bleomycin |
| Blinatumomab |
| Bortezomib |
| Brentuximab |
| Cabazitaxel |
| Carboplatin |
| Carfilzomib |
| Cetuximab |
| Cidofovir |
| Cisplatin |
| Cisplatin and Mannitol |
| Cladribine |
| Crizanlizumab-tmca |
| Cyclophosphamide |
| Cyclophosphamide (Ingenus) |
| Cytarabine |
| Dacarbazine |
| Dactinomycin |
| Daratumumab |
| Daunorubicin |
| Decitabine |
| Dexrazoxane (Mylan) |
| Docetaxel |
| Dostarlimab-gxly |
| Doxorubicin |
| Doxorubicin in LC Bead |
| Doxorubicin liposomal |
| Durvalumab |
| Eculizumab |
| Elotuzumab |
| Epirubicin |
| Eribulin |
| Etoposide |
| Etoposide phosphate |
| Etoposide, Doxorubicin and Vincristine |
| Fam-trastuzumab |
| Fludarabine |
| Fluorouracil |
| Fosaprepitant |
| Ganciclovir |
| Gemcitabine |
| Idarubicin |
| Ifosfamide |
| Infliximab |
| Infliximab-abda |
| Infliximab-dyyb |
| Ipilimumab |
| Irinotecan |
| Irinotecan liposomal |
| Iron Sucrose |
| Leucovorin |
| Lurbinectedin |
| Mesna |
| Mesna and Cyclophosphamide |
| Methotrexate |
| Mitomycin |
| Mitoxantrone |
| Nivolumab |
| Oxaliplatin |
| Paclitaxel |
| Paclitaxel (protein bound) |
| Panitumumab |
| Pegaspergase |
| Pembrolizumab |
| Pemetrexed |
| Pertuzumab |
| Polatuzumab vedotin-piiq |
| Pralatrexate |
| Rituximab |
| Rituximab-abbs |
| Rituximab-pvvr |
| Romidepsin |
| Temsirolimus |
| Tisotumab vedotin |
| Topotecan |
| Trastuzumab |
| Trastuzumab-anns |
| Trastuzumab-qyyp |
| Vedolizumab |
| Vinblastine |
| Vincristine |
| Vinorelbine |
File details come from the government source that posted it. Updated .